SearchCLICK/CONVOKE is a 22-week double blind digital therapeutic study that examines the efficacy of CT-155 as an adjunct treatment for patients diagnosed with experiential negative symptoms of schizophrenia. CT-155 is a novel PDT being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI), collectively, the study “sponsor.” CT-155 delivers an interactive, software-based intervention for experiential negative symptoms of schizophrenia.
Study Length
22 weeksDisorder/Condition
SchizophreniaInclusion Criteria
- Outpatient,
- 18 years of age or older,
- fluent in written and spoken English,
- Is on a stable dose of antipsychotic medication(s) for at least 12 weeks prior,
- Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or greater, or a smartphone with an Android operating system (OS) 10 or greater.
Study Description (brief)
CLICK/CONVOKE is a 22-week double blind digital therapeutic study that examines the efficacy of CT-155 as an adjunct treatment for patients diagnosed with experiential negative symptoms of schizophrenia. CT-155 is a novel PDT being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI), collectively, the study “sponsor.” CT-155 delivers an interactive, software-based intervention for experiential negative symptoms of schizophrenia.
Study Contact
For more information about this study, please contact Jadaera Lorenzo, MA, at (212) 866-2690 or Jadaera.Lorenzo@omh.ny.gov.
Exclusion Criteria
- Is currently treated with more than two antipsychotic medications (including more than two dosage forms),
- Is currently receiving or has received psychotherapy within 3 months prior,
- has a current diagnosis of substance or alcohol use disorder.